<DOC>
	<DOCNO>NCT02564744</DOCNO>
	<brief_summary>A Multicenter Open-Label Phase 2 Study IMGN529 combination rituximab Patients relapse refractory B-Cell lymphoma Other Forms Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>IMGN529 Combination With Rituximab Patients With Relapsed and/or Refractory DLBCL Other Forms NHL</brief_title>
	<detailed_description>A Phase 2 Study Evaluate Efficacy , Tolerability , Pharmacokinetics Pharmacodynamics IMGN529 Combination Rituximab Patients Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma Other Forms Non-Hodgkin 's Lymphoma</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Pathologically confirm relapse and/or refractory DLBCL , FL , MZL/MALT , MCL , Sponsor approve NHL subtypes . Patients must evaluable measurable disease accordance International Working Group Guidelines Lymphoma . Must receive least one six prior treatment regimen . Prior treatment antiCD20 agent , either alone combination , allow . Men woman â‰¥18 year age Patients must ECOG Performance Status 0 2 . Patients HBsAg + ( must PCR negative ) take antiviral . Patients diagnosis CLL small lymphocytic lymphoma ( SLL ) . Patients active hepatitis A , B C infection uncontrolled intercurrent illness . Women pregnant breast feeding . Patients receive prior therapy antiCD37targeting antibody drug conjugate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>